Simulations Plus to Present at the 8th Annual LD Micro Invitational Investor Conference on June 5, 2018

Published: Jun 01, 2018

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (NASDAQ: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, and chemical industries, today announced that it will participate in the 8th Annual LD Micro Invitational Investor Conference to be held at the Luxe Sunset Boulevard Hotel in Los Angeles. John DiBella, president of its Lancaster division, will present on Tuesday, June 5, 2018, at 9:30 a.m. Pacific Time and hold one-on-one meetings with institutional investors throughout the day.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space. In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. The firm hosts several influential conferences annually (Invitational, Summit, and Main Event) and will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe. For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting services for regulatory submissions and quantitative systems pharmacology models for drug-induced liver injury and nonalcoholic fatty liver disease. The company is a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical, biotechnology, and chemical agents. Our software is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, chemical, and consumer goods companies and regulatory agencies worldwide. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation. For more information, visit our website at www.simulations-plus.com.

Follow us on Twitter | LinkedIn

Contacts

Simulations Plus Investor Relations
Ms. Renee Bouche, 661-723-7723
renee@simulations-plus.com
or
Hayden IR
Mr. Cameron Donahue, 651-653-1854
cameron@haydenir.com

 
 

Source: Simulations Plus, Inc.

Back to news